Carolyn F McCabe1, Wei Perng2,3. 1. Department of Nutritional Sciences, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI, USA. 2. Department of Nutritional Sciences, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI, USA. perngwei@umich.edu. 3. Department of Epidemiology, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI, USA. perngwei@umich.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to describe ways in which metabolomics may enhance understanding of gestational diabetes mellitus (GDM) etiology and refine current diagnostic criteria. RECENT FINDINGS: Current clinical recommendations suggest screening for GDM between 24 and 28 of gestational weeks using an oral glucose tolerance test. Despite this consensus, there are discrepancies regarding the exact criteria for GDM diagnosis. Further, emerging evidence has unveiled heterogeneous physiological pathways underlying GDM-specifically, GDM with defective insulin secretion vs. sensitivity-that have important implications for disease diagnosis and management. The objectives of this review are threefold. First, we seek to provide a brief summary of current knowledge regarding GDM pathophysiology. Next, we describe the potential role of metabolomics to refine and improve the prediction, screening, and diagnosis of GDM. Finally, we propose ways in which metabolomics may eventually impact clinical care and risk assessment for GDM and its comorbidities.
PURPOSE OF REVIEW: The purpose of this review is to describe ways in which metabolomics may enhance understanding of gestational diabetes mellitus (GDM) etiology and refine current diagnostic criteria. RECENT FINDINGS: Current clinical recommendations suggest screening for GDM between 24 and 28 of gestational weeks using an oral glucose tolerance test. Despite this consensus, there are discrepancies regarding the exact criteria for GDM diagnosis. Further, emerging evidence has unveiled heterogeneous physiological pathways underlying GDM-specifically, GDM with defective insulin secretion vs. sensitivity-that have important implications for disease diagnosis and management. The objectives of this review are threefold. First, we seek to provide a brief summary of current knowledge regarding GDM pathophysiology. Next, we describe the potential role of metabolomics to refine and improve the prediction, screening, and diagnosis of GDM. Finally, we propose ways in which metabolomics may eventually impact clinical care and risk assessment for GDM and its comorbidities.
Authors: Jamie V de Seymour; Cathryn A Conlon; Karolina Sulek; Silas G Villas Bôas; Lesley M E McCowan; Louise C Kenny; Philip N Baker Journal: Acta Diabetol Date: 2014-07-27 Impact factor: 4.280
Authors: Boyd E Metzger; Steven G Gabbe; Bengt Persson; Thomas A Buchanan; Patrick A Catalano; Peter Damm; Alan R Dyer; Alberto de Leiva; Moshe Hod; John L Kitzmiler; Lynn P Lowe; H David McIntyre; Jeremy J N Oats; Yasue Omori; Maria Ines Schmidt Journal: Diabetes Care Date: 2010-03 Impact factor: 17.152
Authors: Thomas J Wang; Martin G Larson; Ramachandran S Vasan; Susan Cheng; Eugene P Rhee; Elizabeth McCabe; Gregory D Lewis; Caroline S Fox; Paul F Jacques; Céline Fernandez; Christopher J O'Donnell; Stephen A Carr; Vamsi K Mootha; Jose C Florez; Amanda Souza; Olle Melander; Clary B Clish; Robert E Gerszten Journal: Nat Med Date: 2011-03-20 Impact factor: 53.440
Authors: Goncalo Graca; Iola F Duarte; Antonio S Barros; Brian J Goodfellow; Silvia O Diaz; Joana Pinto; Isabel M Carreira; Eulalia Galhano; Cristina Pita; Ana M Gil Journal: J Proteome Res Date: 2010-10-11 Impact factor: 4.466
Authors: William L Lowe; Denise M Scholtens; Lynn P Lowe; Alan Kuang; Michael Nodzenski; Octavious Talbot; Patrick M Catalano; Barbara Linder; Wendy J Brickman; Peter Clayton; Chaicharn Deerochanawong; Jill Hamilton; Jami L Josefson; Michele Lashley; Jean M Lawrence; Yael Lebenthal; Ronald Ma; Michael Maresh; David McCance; Wing Hung Tam; David A Sacks; Alan R Dyer; Boyd E Metzger Journal: JAMA Date: 2018-09-11 Impact factor: 56.272
Authors: Miriam Leitner; Lena Fragner; Sarah Danner; Nastassja Holeschofsky; Karoline Leitner; Sonja Tischler; Hannes Doerfler; Gert Bachmann; Xiaoliang Sun; Walter Jaeger; Alexandra Kautzky-Willer; Wolfram Weckwerth Journal: Front Mol Biosci Date: 2017-12-21
Authors: Yu Liu; Alan Kuang; James R Bain; Michael J Muehlbauer; Olga R Ilkayeva; Lynn P Lowe; Boyd E Metzger; Christopher B Newgard; Denise M Scholtens; William L Lowe Journal: J Clin Endocrinol Metab Date: 2021-10-21 Impact factor: 6.134
Authors: Khalid Khalaf Alharbi; Abdulrahman Mohammed Al-Sulaiman; Khalid Muath Bin Shedaid; Ali M Al-Shangiti; Mohammed Marie; Yazeed A Al-Sheikh; Imran Ali Khan Journal: Ann Saudi Med Date: 2019-10-03 Impact factor: 1.526